Biotechnology

Sanyou Biopharmaceuticals Launches Advanced Intelligent R&D Service Platform

SHANGHAI, March 12, 2024 /PRNewswire/ -- Sanyou Biopharmaceutical Co., Ltd. is delighted to announce the official launch of the "Sanyou Intelligent Innovative Biologics R&D Service Platform," representing a transformative advancement in biopharmaceutical research and development. Our platform en...

2024-03-13 09:00 1263

Novel Molecules From Generative AI to Phase II: First Novel TNIK Inhibitors for Fibrotic Diseases Discovered and Designed Using Generative AI

* A study published in Nature Biotechnology presents the entire journey of INS018_055, from AI algorithms to Phase II clinical trials for the first time. * Raw data from 13 preclinical experiments and 3 clinical trials referenced in this study can be accessed by visiting Insilico'sdata room <...

2024-03-13 08:00 2114

Mabwell to Present Pre-clinical Results at the 2024 American Association for Cancer Research (AACR) Annual Meeting

SHANGHAI, March 12, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that it will present results of three preclinical studies as poster presentation at the AACR Annual Meeting to be held inSan Diego, USA, from April 5...

2024-03-12 22:00 1405

GenScript Biotech Announces 2023 Annual Results with a Five-Year CAGR stands at 30%

R&D Innovation to Lead the Future, Deepening Customer Value Creation * Sustained High Revenue Growth: GenScript Group's five-year CAGR stands at an impressive 30%, with a strong global operation and stable cash flow. In 2023, the group's best-in-class cell therapy product CARVYKTI®, achieved sa...

2024-03-12 20:15 2211

Metabolon and Cardiff University Centre for Neuropsychiatric Genetics and Genomics Forge Alliance to Propel Multiple Sclerosis Research

Partnership will investigate the underlying disease mechanisms of multiple sclerosis (MS) with the potential of finding new relevant drug targets MORRISVILLE, N.C., March 12, 2024 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of li...

2024-03-12 20:05 1733

Longbio Pharma Presented Positive Phase 1 Results for LP-003 at 2024AAD

SAN DIEGO, March 12, 2024 /PRNewswire/ -- Longbio Pharma (Suzhou) Co., Ltd. (referred to as "Longbio Pharma"), a leading biotech company dedicated to developing innovative protein treatments for allergy, respiratory, dermatology, hematology, ophthalmology, and other autoimmune and rare diseases, ...

2024-03-12 20:00 1190

Ajinomoto Bio-Pharma Services Garners Six 'CDMO Leadership Awards,' Further Establishing Its Industry Excellence

SAN DIEGO and TOKYO and WETTEREN, Belgium, March 12, 2024 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, received CDMO Leadership Awards in all six categories - Capabilities, Compatibility,...

2024-03-12 20:00 1704

Innovating the Future: ISoOR 2024 Annual Meeting Achieves Remarkable Success

SINGAPORE, March 12, 2024 /PRNewswire/ -- From March 7 to 8, 2024, the International Society of Organoid Research (ISoOR) convened its 2024 annual meeting, after the successful conference inSingapore last year. This year, the conference was held in the vibrant city ofShanghai, China, reflecting t...

2024-03-12 11:57 1527

TFS HealthScience Unveils Asia Pacific Expansion, Elevating Patient Access and Innovation

LUND, Sweden, March 12, 2024 /PRNewswire/ -- TFS HealthScience (TFS), a leading global Contract Research Organization (CRO), announces its expansion into the Asia Pacific (APAC) region, with the establishment of an operational base in Melbourne, Australia. This strategic move marks a significant m...

2024-03-12 10:52 1623

Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting

ROCKVILLE, Md. and SUZHOU, China, March 12, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmu...

2024-03-12 08:00 1634

SK Biopharmaceuticals Announces 100,000 Patients Globally Have Been Treated with Cenobamate Through Sales of XCOPRI® and ONTOZRY® in the U.S., Europe, Israel, and Canada

Milestone Coincides with SK Biopharmaceuticals' Global Plan Expanding Cenobamate Access to More Than 100 Markets Worldwide SEOUL, South Korea and ROME, March 12, 2024 /PRNewswire/ -- SK Biopharmaceuticals Co., Ltd., a global biotech focused on developing treatments for central nervous system (CN...

2024-03-12 08:00 1389

Appointment of Dr Darren Patti to Group Chief Operating Officer

MELBOURNE, Australia, March 12, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to announce the appointment of Dr.Darren Patti as Group Chief Operating Officer (COO), effective 11 March 2024. Dr. Patti joined Telix in March 2021 to lead the Company'...

2024-03-12 05:44 1373

Mabwell to Present ADC Platform IDDC™ and the Latest Study Results of Multiple Novel ADCs at the 14th World ADC London

SHANGHAI, March 11, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that it will present its next generation ADC platform IDDC™ and the latest study results of multiple novel ADCs (9MW2821, 7MW3711, 9MW2921) developed...

2024-03-11 22:00 1139

Medicilon has appointed Dr. Qingcong Lin as President of Medicilon USA Corp., further deepening the global strategic layout

BOSTON, March 11, 2024 /PRNewswire/ -- Medicilon, a one-stop pharmaceutical preclinical research and developmentCRO can simultaneously meet Chinese and American drug discovery and development needs (including GLP standards) promptly and efficiently with fast initiation times.Over the past 20 year...

2024-03-11 20:30 1108

ImmunAbs Announces Conclusion of Phase 1 Clinical Trial, Revealing Positive Topline Results

SEOUL, South Korea, March 11, 2024 /PRNewswire/ -- ImmunAbs, a leading clinical-stage biotechnology company focused on developing novel antibody therapeutics, today announced the successful completion of the Phase 1 clinical trial for IM-101. IM-101 is a humanized monoclonal antibody targeting...

2024-03-11 17:00 1818

RemeGen Presents Oral Presentation on Evaluation of Its Proprietary Disitamab Vedotin (RC48) for Cervical Cancer at ESGO 2024

YANTAI, China, March 11, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, recently gave an oral presentation on an interim analysis of the evaluation of the Company's proprietary Disitamab ...

2024-03-11 10:36 1304

Mabwell to Present the Clinical Data of 9MW2821 in Cervical Cancer as Focused Plenary Oral Presentation at 2024 Society of Gynecologic Oncology Annual Meeting on Women's Cancer

SHANGHAI, March 8, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that it will present the clinical study results on the efficacy and safety of the novel Nectin-4-targeting ADC 9MW2821 for patients with recurrent or ...

2024-03-08 22:00 1630

TransThera Announced Global Phase 3 Clinical Trial for Cholangiocarcinoma Authorized in the European Union and Orphan Drug Designation for Tinengotinib to Treat Biliary Tract Cancer Granted by European Medicines Agency

NANJING, China and GAITHURSBURG, Md., March 8, 2024 /PRNewswire/ -- TransThera, a clinical-stage biopharmaceutical company dedicated to innovating differentiated drugs globally, today announced that the randomized, controlled, global multicenter Phase 3 trial (FIRST-308) of tinengotinib versus ph...

2024-03-08 21:00 2367

Chime Biologics Achieves ISO 27001 Certification to Strengthen Information Security in the CDMO Industry

WUHAN, China, March 7, 2024 /PRNewswire/ -- Chime Biologics, a leading global CDMO that enables its partners' success in biologics, today announced that it has obtained ISO/IEC 27001:2022 certification on information security management systems. After passing rigorous reviews on all the items of...

2024-03-07 22:00 1171

Innovent released the results of two clinical studies of IBI311 (an anti-IGF-1R monoclonal antibody) in oral presentations at the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024

ROCKVILLIE, Md. and SUZHOU, China, March 7, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and...

2024-03-07 11:53 2387
12345678 ... 275